Want to see ALLR full AI Analyst Report?
ALLR Stock Chart & Stats
$1.14
-$0.01(-0.99%)
At close: 4:00 PM EST
$1.14
-$0.01(-0.99%)
Day’s Range― - ―
52-Week Range$0.77 - $2.35
Previous CloseN/A
Volume542.33K
Average Volume (3M)146.33K
Market Cap
$20.37M
Enterprise Value$9.09
Total Cash (Recent Filing)$19.81M
Total Debt (Recent Filing)$21.50M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Oct 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding15,910,724
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.25Price Target Upside799.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary DRP® PlatformAllarity’s DRP® platform is a structural competitive asset: patient-selection biomarkers can materially raise trial success rates and make candidates more attractive to partners. Durable benefit includes faster enrollment, clearer regulatory endpoints, and higher commercial differentiation for companion diagnostics.
Stenoparib Diagnostic Patent ExclusivityThe granted U.S. patent (and complementary Europe/Australia protection) creates a long-term IP moat for the stenoparib companion diagnostic, supporting exclusivity through pivotal commercial windows. This strengthens licensing leverage, reduces immediate competitive entry risk and bolsters partner negotiations.
Low Leverage And Positive EquityZero reported debt and positive equity provide structural financial flexibility versus peer biotechs with high leverage. This lowers near-term bankruptcy risk, preserves ability to pursue R&D or delayed commercialization, and gives management optionality when sequencing financing or deals.
Bears Say
High Operating Cash BurnSustained negative operating and free cash flow at this magnitude vs. minimal revenues implies a structurally cash-consuming model. Without durable revenue or major partnering, the company will need repeated capital raises, constraining long-term strategy and increasing dilution risk for shareholders.
Minimal Recurring RevenueRevenue is immaterial relative to R&D and operating burn, reflecting a pre-commercial biotech reliant on trial progress and external funding. The lack of recurring product revenue makes profitability distant and heightens execution risk around clinical readouts and partner monetization.
Dilution And Financing DependenceRecent approvals to expand equity incentives and to issue additional shares under a purchase agreement signal ongoing financing reliance. Structurally, this increases the probability of shareholder dilution and may pressure management to prioritize near-term financing over longer-term value capture.
Allarity Therapeutics News
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.77 and its highest was $2.35 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $20.37M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is Oct 13, 2026 which is in 80 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Allarity Therapeutics, Inc. released its earnings results on May 15, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Undervalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 15,910,724 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Allarity Therapeutics, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.926%.
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
ALLR Stock 12 Month Forecast
Average Price Target
$10.25
▲(799.12% Upside)
Technical Analysis
Ownership Overview
7.69% Insiders
1.90% Mutual Funds
1.49% Other Institutional Investors
87.85% Public Companies and
Individual Investors